Trial Profile
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary) ; Adalimumab
- Indications Ankylosing spondylitis; Axial spondyloarthritis
- Focus Registrational; Therapeutic Use
- Acronyms COAST-V
- Sponsors Eli Lilly and Company
- 15 Nov 2023 Results of post hoc analysis (N=81) assessing the association between treatment response at Week (W)12 and W24, and attainment of the ASDAS < 2.1 treat to target recommendation at W52 in patients with radiographic axSpA treated with ixekizumab presented at the ACR Convergence 2023
- 15 Nov 2023 Post-hoc results assessing post-hoc analyses of patients with MRI available at baseline and week 16 for placebo, Ixekizumab Q2W, Ixekizumab Q4W and adalimumab groups were presented at the ACR Convergence 2023.
- 03 Jun 2023 Post-hoc results (n=587) from COAST-V, COAST-X, COAST-W studies presented at the 24th Annual Congress of the European League Against Rheumatism.